Articles

Combining their resources

Warburg Pincus acquires ReSearch Pharmaceutical Services in cash deal worth $227.3 million
Written byLori Lesko
| 3 min read

FORT WASHINGTON, Pa.—ReSearch Pharmaceutical Services Inc. (RPS) has agreed to be bought by global private equity firm Warburg Pincus LLC, in an all-cash deal valued at approximately $227.3 million.In June, clinical research firm RPS filed for an initial public offering with U.S. regulators.

On Dec. 28, RPS announced an agreement to sell the company to affiliates of Warburg Pincus at $6.10 per share. RPS' board of directors unanimously approved the acquisition agreement and recommended that the company's shareholders approve the transaction.

Warburg Pincus has 37.3 million outstanding shares, according to the company's latest regulatory filing. RPS anticipates the closing of the transaction will occur sometime this month.

Executives from RPS and Warburg Pincus declined requests from ddn for interviews, preferring to let joint press statements suffice.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.